An integrated approach to cardioprotection in lymphomas

Maraldo, M.V.; Levis, Mario; Andreis, Alessandro; Armenian, Saro H.; Bates, James E.; Brady, J.L.; Ghigo, Alessandra; Lyon, Alexander R.; Manisty, Charlotte; Ricardi, Umberto; Aznar, Marianne C.; Filippi, Andrea Riccardo

doi:10.1016/s2352-3026(22)00082-5

Cited by 9 publications

(3 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11,12 Anthracyclines develop their toxicities by producing cytotoxic reactive oxygen species through several mechanisms, including DNA topoisomerase inhibition, DNA damage response activation, and mitochondrial biogenesis and mitochondrial iron metabolism disruption. 13 The above-mentioned cohort study revealed an association between anthracyclines and an increased risk of CHF (HR = 2.71, p < 0.001) and arrhythmia (HR = 1.61, p < 0.01). However, anthracyclines were not associated with an increased risk of valvular heart disease (HR = 0.84, p = 0.58) or acute coronary syndrome (HR = 1.32, p = 0.24).…”

Section: Anthracyclinesmentioning

confidence: 89%

See 1 more Smart Citation

Cardiovascular Issues in Patients with Malignant Lymphoma: A Narrative Review

Shibusawa

Imamine²

2023

MRAJ

View full text Add to dashboard Cite

Cardiovascular issues are important concerns in malignant lymphoma treatment. These issues can be broadly categorized into two groups: the invasion of malignant lymphoma into the heart and cardiovascular disease related to malignant lymphoma treatment. In terms of malignant lymphoma invasion of the heart, the presence of a heart lesion of malignant lymphoma often presents with heart-related symptoms and findings such as chest pain, heart failure, and arrhythmias. Notably, heart failure and arrhythmias can be fatal. The identification of heart lesions of malignant lymphoma will result in appropriate management and survival improvement. As for cardiovascular disease associated with malignant lymphoma treatment, the incidence and types of cardiovascular disease, management, and follow-up planning should be identified before starting treatment. This identification and plan will allow an understanding of the risk of developing cardiovascular disease and appropriate management and follow-up. In clinical practice, it is important to keep in mind that cardiac issues in patients with malignant lymphoma should be identified, assessed, and managed before initiating treatment.

show abstract

Section: Anthracyclinesmentioning

confidence: 89%

“…Currently, radiation therapy with a low total dose and a relatively small irradiated area is being used to reduce these AEs. 13 Thus, CVD associated with radiation therapy is important in long-term follow-up after treatment. Take home message ・Anthracycline cardiotoxicity is dose-dependent.…”

Section: Radiotherapymentioning

confidence: 99%

Cardiovascular Issues in Patients with Malignant Lymphoma: A Narrative Review

Shibusawa

Imamine²

2023

MRAJ

View full text Add to dashboard Cite

show abstract

“…Alongside with the development of systemic regimens, radiotherapy have dramatically evolved through the reduction in treatment fields and doses and the continuous advancements in the precision of the delivery techniques ( 2 , 3 ). These evolutions are expected to significantly improve the therapeutic index of lymphoma patients in several settings, and in particular to reduce treatment-related toxicity events ( 4 ). In addition, the synergistic association of novel systemic agents and modern radiotherapy needs to be explored for the promising “pro-immunogenic” role of RT in combination with immunotherapy agents in different hematological scenarios.…”

mentioning

confidence: 99%